Published in Leukemia on February 01, 2007
Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell (2008) 3.31
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2011) 1.25
Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica (2010) 1.19
Childhood B-acute lymphoblastic leukemia: a genetic update. Exp Hematol Oncol (2014) 1.01
Genetic variants modify susceptibility to leukemia in infants: a Children's Oncology Group report. Pediatr Blood Cancer (2012) 0.97
Modeling human infant MLL leukemia in mice: leukemia from fetal liver differs from that originating in postnatal marrow. Blood (2011) 0.95
Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia (2014) 0.90
Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Exp Hematol (2014) 0.84
MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle (2014) 0.83
Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Clin Cancer Res (2015) 0.82
ARID5B and IKZF1 variants, selected demographic factors, and childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leuk Res (2013) 0.82
MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children's Oncology Group (COG) study. Pediatr Blood Cancer (2011) 0.80
Use of Genome Engineering to Create Patient Specific MLL Translocations in Primary Human Hematopoietic Stem and Progenitor Cells. PLoS One (2015) 0.79
Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer (2015) 0.79
Discordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin. Blood (2009) 0.79
Concise review: hematopoietic stem cell aging and the prospects for rejuvenation. Stem Cells Transl Med (2014) 0.78
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood (2016) 0.77
Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemia. PLoS One (2015) 0.75
Identification of the MYST3-CREBBP fusion gene in infants with acute myeloid leukemia and hemophagocytosis. Rev Bras Hematol Hemoter (2016) 0.75
The role of the anterior prefrontal cortex in human cognition. Nature (1999) 4.25
Prenatal origin of acute lymphoblastic leukaemia in children. Lancet (1999) 4.21
New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med (2000) 3.77
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia (2005) 3.09
Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med (2001) 2.94
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 2.86
IL-1 stimulates IL-6 production in endothelial cells. J Immunol (1989) 2.85
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
The MLL recombinome of acute leukemias in 2013. Leukemia (2013) 2.55
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 2.48
Screening for mental health: validity of the MHI-5 using DSM-IV Axis I psychiatric disorders as gold standard. Psychiatry Res (2001) 2.42
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia (2007) 2.40
Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Blood (1997) 2.40
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia (2003) 2.29
Redesign of PCR primers for mitochondrial cytochrome c oxidase subunit I for marine invertebrates and application in all-taxa biotic surveys. Mol Ecol Resour (2013) 2.27
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain (2005) 2.25
Factors influencing remission from alcohol dependence without formal help in a representative population sample. Addiction (2001) 2.22
Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom (2004) 2.20
Juvenile myelomonocytic leukemia. Blood (1997) 2.19
IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia (2010) 2.17
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11
Acute promyelocytic leukemia: from genetics to treatment. Blood (1994) 2.09
Phlebitis rate and time kinetics of short peripheral intravenous catheters. Infection (2004) 2.06
Volumetric spectroscopic imaging with spiral-based k-space trajectories. Magn Reson Med (1998) 2.05
Cloning of DNA fragments complementary to tobacco nitrate reductase mRNA and encoding epitopes common to the nitrate reductases from higher plants. Mol Gen Genet (1987) 2.05
[Bilateral salivary gland swelling with pitfalls]. Med Klin (Munich) (1994) 2.03
Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care (2001) 2.02
In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood (1995) 2.00
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia (2012) 1.93
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood (2000) 1.93
Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A (1991) 1.90
Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology (2005) 1.90
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.88
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia (2009) 1.86
Expression of the potato tuber ADP-glucose pyrophosphorylase in Escherichia coli. J Biol Chem (1993) 1.83
Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia (1999) 1.83
Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol (1989) 1.80
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia (2007) 1.79
North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet (1998) 1.75
Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg (1997) 1.74
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J (1999) 1.73
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol (1995) 1.72
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia (2004) 1.71
Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. Cancer Res (2000) 1.71
Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles. J Neurol Neurosurg Psychiatry (2009) 1.70
Biological and therapeutic aspects of infant leukemia. Blood (2000) 1.70
Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res (2001) 1.70
Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood (1998) 1.69
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia (2008) 1.67
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol (2003) 1.67
Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia (2011) 1.67